Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

A newly FDA-cleared personalized brain stimulation treatment for PTSD achieved a 68% remission rate in a clinical trial, with patients experiencing a 52% reduction in symptoms—more than four times the remission rate of existing medications.

This is an early clinical trial. The full findings are still being prepared for public release, and results come from different studies and should not be directly compared to medication outcomes.